Recently, a number of proteomic studies have identified C3a as biomarker candidates for colon cancer[27], chronic hepatitis C and related hepatocellular carcinoma[28], insulin resistance/type-2 diabetes[29] and chronic lymphoid malignancies[30]. This evidence concerns the gene C3 and hepatocellular carcinoma.